When Clinical Care Depends on the Answer: The Challenges of Assessing Germline Cancer Gene Variants.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
   Review
2. Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation.Journal of personalized medicine · 2021
   Article
3. Patient perspectives on variant reclassification after cancer susceptibility testing.Molecular genetics & genomic medicine · 2020
   Article
4. The effects of genomic germline variant reclassification on clinical cancer care.Oncotarget · 2019
   Article

Corrections and comments

• Comment on
  Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.2016

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as